We’ are excited to highlight an upcoming presentation at the joint European Neonatal Societies (jENS) Congress 2025, where new evidence will be shared on the role of serum calprotectin in the early diagnosis of neonatal infections.
The short oral presentation, “Serum calprotectin as a routine biochemical parameter to improve early diagnosis of neonatal infections” will be delivered by Sabrina Holzapfel and Holger Michel from the University Children’s Hospital Regensburg (KUNO), Hospital St. Hedwig of the Order of St. John, University of Regensburg, on Thursday, 23rd October. The Gentian GCAL® Calprotectin Immunoassay has been used in the study.
Early identification of neonatal infections remains a major challenge. Conventional biomarkers such as C-reactive protein (CRP) and IL-6 are valuable, yet each has limitations in timing and specificity. At this year’s jENS, new findings will be shared demonstrating how serum calprotectin can complement these markers, supporting more accurate diagnosis and informed antibiotic decisions.
The study, performed with the Gentian GCAL® Calprotectin Immunoassay demonstrates calprotectin’s potential as a fast, reliable, automated assay requiring minimal sample volume – making it well suited for routine clinical practice.
Calprotectin, a neutrophil-derived protein complex (S100A8/ S100A9), is a key mediator of innate immunity. Released rapidly during inflammation, it acts as an alarmin and participates in both pro-inflammatory signalling and antimicrobial defence. Circulating calprotectin rises soon after infection onset and correlates with the degree of neutrophil activation and systemic inflammation. This makes it a valuable biomarker for early detection of infection and for assessing disease severity in clinical practice.1-4
The GCAL® assay is intended for quantitative determination of calprotectin in plasma and serum as an aid in detection and assessment of inflammation and inflammatory response to infections. The test can be used for early detection and assessment of the inflammatory response to severe infections, where it is critical to get access to the results as soon as possible.
Explore GCAL® in your clinical practice and laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.
*The GCAL® immunoassay is developed and manufactured by Gentian AS. GCAL® is CE-marked in compliance with IVDR 2017/746 (CE 0123). The assay might not be registered for use in your country of residence and may not comply with applicable laws or regulations in that country. The assay is not cleared for use in the USA.